# Michael Chambers

> Michael Chambers is a Series A investor at AltraVax (Fargo) backing Biotechnology and Genetics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [AltraVax](https://shizune.co/investors/profile/altravax)
- Location: Fargo, United States
- Total investments: 3
- Last investment: Jan 2022
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chambersmichael

Michael Chambers is a Series A investor at AltraVax in Fargo focused on Biotechnology and Genetics. Michael Chambers is the Co-Founder at Agathos Biologics.Michael’s vision and leadership of Aldevron has resulted in several milestones including the 2004 acquisition of Genovac Antibody Technology of Freiburg, Germany; the 2009 expansion of protein production in Madison, Wisconsin; private equity transactions by TA Associates in 2017 and EQT in2020; and the purchase of Aldevron by Danaher for $9.6 billion in 2021. Michael is committed to ethical pharmaceutical development and his leadership will enable Agathos to create new paradigms in biotechnology to achieve these goals. Michael received Bachelor of Science degrees in biotechnology, chemistry, and microbiology from North Dakota State University.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $30M–$55M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 100% |
| Genetics | 2 | 67% |
| Life Science | 2 | 67% |
| Biopharma | 1 | 33% |
| Education | 1 | 33% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Venture - Series Unknown | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| 64x Bio | A comprehensive platform and product suite for advanced therapeutics. | $55M | Series A | Jan 19, 2022 |  |
| Kytopen | Kytopen develops genome engineering platforms that enable cell therapy research and manufacturing. The company provides non-viral gene delivery systems that facilitate the delivery of mRNA, DNA, and CRISPR Cas9 RNP into cells while retaining cell functionality. Its Flowfect® technology allows high-throughput transfections and scalable optimizationfrom small experiments to large-scale manufacturing.Kytopen’s platforms include Flowfect Discover™ for automated small-volume screening and Flowfect TX® for large-scale delivery, supporting drug discovery and process development. The systems integrate electrical, mechanical, and chemical forces to fine-tune gene delivery, enabling controlled and predictable scaling. The company’s solutions focus on removing bottlenecks in gene delivery and streamlining the transition from laboratory research to therapeutic production. | $30M | Series A | Sep 28, 2021 |  |
| Erbi Biosystems | Erbi Biosystems is a transformative microfluidic bioprocess instrumentation company. |  | Venture - Series Unknown | Jan 04, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Northpond Ventures](https://shizune.co/investors/profile/northpond-ventures) — VC Fund, 3 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- [Alix Ventures](https://shizune.co/investors/profile/alix-ventures) — VC Fund, 1 deal together
- [BoxGroup](https://shizune.co/investors/profile/boxgroup) — VC Fund, 1 deal together
- [Fifty Years](https://shizune.co/investors/profile/fifty-years) — VC Fund, 1 deal together
- [First Round Capital](https://shizune.co/investors/profile/first-round-capital) — VC Fund, 1 deal together

## About AltraVax

VC Fund · Sunnyvale, United States

Altravax was incorporated in 2009 and is a privately held biopharmaceutical company based in North Dakota with research facilities in Sunnyvale, California. The Company is focused on the discovery and development of novel products to fight infectious diseases and other conditions. Our proprietary Immunogen Optimization System™ (IOS) offers uniqueopportunities to create novel vaccines or improve currently available alternatives to fill unmet medical needs. The Company has a robust pipeline of candidates at various stages of development, including a therapeutic vaccine against chronic hepatitis B infection and a preventive vaccine against all four dengue virus. Altravax seeks strategic alliances to develop these lead candidates for clinical testing.

3 contacts available at AltraVax.

| Name | Title | Profile |
| --- | --- | --- |
| Michael Chambers | CEO | https://shizune.co/investors/profile/michael-chambers |
| Robert Whalen | CSO | https://shizune.co/investors/profile/robert-whalen |
| Sean Du | COO | https://shizune.co/investors/profile/sean-du |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Life Science Angel Investors](https://shizune.co/investors/life-science-angel-investors)

## FAQ

### What does Michael Chambers invest in?

Michael Chambers invests primarily in Biotechnology, Genetics and Life Science startups, most often at Series A and Venture - Series Unknown stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Michael Chambers's check size?

Michael Chambers typically joins rounds of $30M–$55M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Michael Chambers participates in.

### When did Michael Chambers last invest?

The most recent investment recorded for Michael Chambers closed in Jan 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co